Immune Design 10-Q 8 Sep 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Sep. 04, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'IMDZ	'
Entity Registrant Name	'Immune Design Corp.	'
Entity Central Index Key	'0001437786	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	16,860,637

Balance_Sheets

Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$18,003	$30,387
Accounts receivable	1,038	87
Inventory	19	17
Prepaid expenses	969	179
Total current assets	20,029	30,670
Property and equipment, net	290	295
Deferred offering costs	1,765	0
Total assets	22,084	30,965
Current liabilities:	'	'
Accounts payable	1,369	866
Accrued liabilities	1,452	1,082
Deferred rent, current	36	27
Total current liabilities	2,857	1,975
Deferred rent, noncurrent	76	94
Convertible preferred stock warrant liability	7,486	3,336
Commitments and contingencies	'	'
Convertible preferred stock, $0.001 par value per share; 12,882,593 and 12,882,593 shares authorized at June 30, 2014 (unaudited) and December 31, 2013, respectively; 9,769,422 and 9,769,422 shares issued and outstanding at June 30, 2014 (unaudited) and December 31, 2013, respectively; liquidation preference of $84,300 and $84,300 at June 30, 2014 (unaudited) and December 31, 2013, respectively	81,394	81,394
Stockholders’ (deficit) equity:	'	'
Common stock, $0.001 par value per share; 15,045,871 and 15,045,871 shares authorized at June 30, 2014 (unaudited) and December 31, 2013, respectively; 369,750 and 369,460 shares issued and outstanding at June 30, 2014 (unaudited) and December 31, 2013, respectively	3	3
Additional paid-in capital	1,229	775
Accumulated deficit	-70,961	-56,612
Total stockholders’ (deficit) equity	-69,729	-55,834
Total liabilities, convertible preferred stock and stockholders’ (deficit) equity	$22,084	$30,965

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Convertible preferred stock	'	'
Par value per share (in USD per share)	$0.00	$0.00
Shares issued (in shares)	9,769,422	9,769,422
Shares outstanding (in shares)	9,769,422	9,769,422
Shares authorized (in shares)	12,882,593	12,882,593
Liquidation preference	$84,300	$84,300
Common stock	'	'
Par value per share (in USD per share)	$0.00	$0.00
Shares issued (in shares)	369,750	369,460
Shares outstanding (in shares)	369,750	369,460
Shares authorized (in shares)	15,045,871	15,045,871

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Licensing revenue	$1,000	$514	$1,000	$704
Product sales	64	368	89	742
Other, net	0	0	0	0
Total revenues	1,064	882	1,089	1,446
Operating expenses:	'	'	'	'
Cost of product sales	18	250	32	462
Research and development	3,883	3,356	7,961	5,899
General and administrative	1,850	914	3,296	1,695
Total operating expenses	5,751	4,520	11,289	8,056
Loss from operations	-4,687	-3,638	-10,200	-6,610
Interest and other income	0	4	1	35
Change in fair value of convertible preferred stock warrant liability	-1,439	0	-4,150	0
Net loss attributable to common stockholders	($6,126)	($3,634)	($14,349)	($6,575)
Earnings Per Share	'	'	'	'
Basic and diluted net loss per share attributable to common stockholders (in USD per share)	($16.57)	($9.84)	($38.81)	($17.99)
Weighted Average Number of Shares Outstanding, Diluted	'	'	'	'
Weighted-average shares used to compute basic and diluted net loss per share attributable to common stockholders (in shares)	369,750	369,460	369,702	365,435

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'
Net loss	($14,349)	($6,575)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	122	221
Compensation related to stock option grants	454	84
Revaluation of convertible preferred stock warrant liability	4,150	0
Other non-cash losses/(gains)	0	-32
Changes in operating assets and liabilities:	'	'
Accounts receivable	-951	-432
Inventory	-2	83
Prepaid expenses	-790	-219
Accounts payable	389	-21
Accrued liabilities	87	-1,041
Deferred rent	-9	68
Net cash used in operating activities	-10,899	-7,864
Investing activities	'	'
Purchases of property and equipment	-117	-119
Proceeds from the sale of property and equipment	0	43
Net cash used in investing activities	-117	-76
Financing activities	'	'
Issuance of common stock	0	6
Deferred offering costs	-1,368	0
Net cash provided (used in) by financing activities	-1,368	6
Net decrease in cash and cash equivalents	-12,384	-7,934
Cash and cash equivalents, beginning of period	30,387	12,762
Cash and cash equivalents, end of period	18,003	4,828
Supplemental schedule of noncash financing activities:	'	'
Accrued offering costs	$397	$0

Description_of_the_Business

Description of the Business	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Description of the Business	'
	Description of the Business
	Immune Design Corp. (we, us or our) is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. We have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. We are developing multiple product candidates from our two discovery platforms, IMDZVex™ or "ZVex™" for short (previously known as DCVex) and GLAAS™, which we believe have the potential to treat a broad patient population. Our product candidates, LV305, CMB305 and G100, utilize multiple immuno-oncology approaches and, we believe, address the shortcomings of existing therapies. LV305 and G100 are in Phase 1 clinical trials and we expect to initiate a Phase 1 clinical trial for CMB305 by the end of the year. CMB305 combines our two platforms in a prime-boost approach that we believe should be more effective than either LV305 or G305 alone. Although we plan to focus our development efforts on CMB305 and G100, we plan to conduct a small exploratory trial to compare LV305 and CMB305 in the same tumor types. After reviewing those data, we may elect to separately develop LV305.
	We were incorporated in February 2008 in the State of Delaware. Our operations are headquartered in Seattle, Washington with additional facilities in South San Francisco, California.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation and Use of Estimates
	The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). To conform with GAAP, the preparation of our financial statements requires management to make judgments, assumptions, and estimates that affect the amounts reported in our financial statements and accompanying notes. Estimates are used for, but not limited to, accruals for clinical trial activity, other accrued liabilities, and assumptions used in determining stock-based compensation expenses and convertible preferred stock warrant liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ materially from those estimates.
	Unaudited Interim Financial Information
	The accompanying unaudited condensed financial statements as of June 30, 2014 and for the three and six months ended June 30, 2014 and 2013 and the related interim information contained within the notes to the financial statements are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited financial statements and in the opinion of management, reflect all normal recurring adjustments necessary for a fair statement of our financial position as of June 30, 2014 and the results of operations and cash flows for the three and six months ended June 30, 2014 and 2013. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ended December 31, 2014 or for other future interim periods or years.
	The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2013 included in our prospectus, dated July 23, 2014, filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.
	Segments
	We operate in one segment and use cash flow as the primary measure to manage our business and do not segment the business for internal reporting or decision-making purposes.
	Reverse Stock Split
	On July 14, 2014, we filed an amendment to our amended and restated certificate of incorporation, effecting a 1-for-8.175 reverse stock split. All issued and outstanding stock and per share amounts contained in our financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.
	Initial Public Offering
	In July 2014, we completed our initial public offering of shares of our common stock (IPO), pursuant to which we issued 5,000,000 shares of our common stock, at a price of $12.00 per share. In August 2014, we sold an additional 410,564 shares of common stock directly to our underwriters when they exercised a portion of their over-allotment at $12.00 per share. We received net proceeds of $60.4 million (inclusive of the exercise of the over-allotment) after deducting underwriting discounts and commissions and offering expenses from the IPO. In connection with the closing of the IPO, all of our outstanding shares of convertible preferred stock automatically converted into 9,769,422 shares of common stock. In July 2014, prior to the completion of the IPO, warrants to purchase 996,940 shares were cash exercised for $8.1 million and resulted in the issuance of an additional 996,940 shares of common stock. Immediately prior to the closing of the IPO, warrants to purchase 978,592 shares were automatically net exercised, resulting in an issuance of an additional 311,923 shares of common stock. The significant increase in shares outstanding in July 2014 is expected to impact the year-over-year comparability of our net loss per share calculations over the next year.
	Deferred Offering Costs
	Deferred offering costs represent legal, accounting and other direct costs related to our efforts to raise capital through our IPO of our common stock. These costs were deferred through the completion of the IPO and on the completion of the IPO will be reclassified to additional paid-in capital as a reduction of the proceeds.
	Comprehensive Loss
	Comprehensive loss is comprised of net loss and certain changes in equity that are excluded from net loss. There was no difference between comprehensive loss and net loss for the three and six months ended June 30, 2014 and 2013.
	Revenue Recognition
	We derive our revenue from collaboration and licensing agreements and the sale of products associated with material transfer, collaboration and supply agreements.
	Licensing fees are recognized when the amounts are earned and determinable during the applicable period. We recognize up-front nonrefundable license fees when due under contractual agreements and when we do not have a continuing obligation to provide services related to the agreement. Revenue associated with nonrefundable up-front license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected term of our continued involvement in the research and development process. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, we recognize such milestones as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process.
	Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable, (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. Payments received in advance of work performed are recorded as deferred revenue.
	Certain agreements from which we derive our revenue include multiple deliverables. We recognize the revenue for each deliverable at fair value determined to be estimated selling price in cases when neither vendor specific objective evidence nor third-party evidence is available.
	Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price to the customer is fixed or determinable; and (4) collectability is reasonably assured. The evaluation of these revenue recognition criteria requires significant management judgment. For instance, we use judgment to assess collectability based on factors such as the customer’s creditworthiness and past collection history, if applicable. If we determine that collection of a payment is not reasonably assured, revenue recognition is deferred until receipt of payment. We also use judgment to assess whether a price is fixed or determinable including, but not limited to, reviewing contractual terms and conditions related to payment terms.
	Revenue from product sales of glucopyranosyl lipid A (GLA), is recognized when the risk of loss has passed to the customer or deferred until such time that risk of loss has passed. All revenues associated from the sale of GLA products supplied by us are reported under product sales with the applicable costs reported under cost of product sales. Product sales consist of the direct costs associated with the manufacture and formulation of GLA, including costs to purchase raw materials, third-party contract manufacturing costs, assay testing and ongoing product stability testing.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB), issued Accounting Standards Update (ASU) No. 2014-09, related to the recognition of revenue. The standard requires entities to recognize revenue through the application of a five step model, which includes identification of the contract, identification of the performance obligations, determination of the transaction price, allocation of the transaction price to the performance obligations, and recognition of revenue as the entity satisfies the performance obligations. ASU 2014-09 is effective retrospectively for annual or interim reporting periods beginning after December 15, 2016, with early application not permitted. We are evaluating the guidance to determine the potential impact on our results of operations, financial condition, cash flows, and financial statement disclosures.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Net Loss Per Share
	We compute net loss per share attributable to common stockholders using the two-class method required for participating securities. We consider all series of our convertible preferred stock to be participating securities. In accordance with the two-class method, earnings allocated to these participating securities, which include participation rights in undistributed earnings, are subtracted from net income to determine total undistributed earnings to be allocated to common stockholders.
	Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. All participating securities are excluded from basic weighted-average common shares outstanding. In computing diluted net loss per share attributable to common stockholders, undistributed earnings are re-allocated to reflect the potential impact of dilutive securities, including stock options and warrants. Diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period. Diluted net loss per share attributable to common stockholders includes any dilutive effect from outstanding stock options and warrants using the treasury stock method.
	The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share attributable to common stockholders calculation because their effect would have been antidilutive for the periods presented:
		Three Months Ended June 30,
		2014	2013
		(unaudited)
	Convertible preferred stock	9,769,422	5,818,356
	Options to purchase common stock	1,802,626	732,445
	Warrants to purchase convertible preferred stock	1,975,532	—
		13,547,580	6,550,801

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	We measure and record cash and cash equivalents and convertible preferred stock warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows:
	Level 1: Quoted prices in active markets for identical assets or liabilities.
	Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Level 1 securities consist of highly liquid money market funds. The fair value of Level 1 assets has been determined using quoted prices in active markets for identical assets.
	In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. The Level 3 liability that is measured at estimated fair value on a recurring basis consists of the convertible preferred stock warrant liability. The estimated fair value of the outstanding convertible preferred stock warrant liability is measured using the income method approach in combination with a Monte Carlo simulation. Inputs used to determine estimated fair value include the estimated fair value of the underlying stock at the valuation measurement date, the multiple scenarios outlining probabilities and the remaining contractual term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the price of the underlying stock.
	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis (in thousands):
			30-Jun-14
			(unaudited)
			LEVEL 1		LEVEL 2		LEVEL 3		TOTAL
	Assets:
	Money market funds		$	17,716	$	—	$	—	$	17,716
	Liabilities:
	Convertible preferred stock warrant liability		$	—	$	—	$	7,486	$	7,486
			31-Dec-13
			LEVEL 1		LEVEL 2		LEVEL 3		TOTAL
	Assets:
	Money market funds		$	30,030	$	—	$	—	$	30,030
	Liabilities:
	Convertible preferred stock warrant liability		$	—	$	—	$	3,336	$	3,336
	We classify the convertible preferred stock warrant liability within Level 3 because the warrant liability is valued using valuation models with significant unobservable inputs. The estimated fair value of warrants accounted for as liabilities was determined on the issuance date and are subsequently remeasured to fair value at each reporting date. The change in fair value of the 2013 warrants is recorded in the statements of operations as a non-operating gain or loss by using a Monte Carlo option pricing model with the following assumptions:
	Upon the issuance in October 2013 of our Series C convertible preferred stock, we used the following assumptions to estimate fair value: equity value of the entity, different conversion prices for different scenarios, time to maturity of 1.7 to 2.0 years under the different exercise scenarios, volatility of 82% and risk free rate of 0.3%.
	For December 31, 2013, we used the following assumptions to estimate fair value: equity value of the entity, different conversion prices for different scenarios, time to maturity of 1.2 to 1.7 years under the different exercise scenarios, volatility of 82% and risk free rate of 0.3%.
	For June 30, 2014, we used the following assumptions to estimate fair value: equity value of the entity, different conversion prices for different scenarios, time to maturity of 0.1 to 1.3 years under the different exercise scenarios, volatility of 102.3% and risk free rate of 0.2%.
	The table below shows the reconciliation of the convertible preferred stock warrant liability measured and recorded at fair value on a recurring basis, using significant unobservable inputs (Level 3) (in thousands):
		Estimated Fair Value
	Balance as of December 31, 2013	$	3,336
	Change in fair value of convertible preferred stock warrant liability (unaudited)	4,150
	Balance as of June 30, 2014 (unaudited)	$	7,486
	Warrants were issued in October 2013 and, as such, there was no convertible preferred stock warrant liability as of June 30, 2013.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventory
	Inventory consists of the following (in thousands):
		June 30,		December 31,
		2014		2013
		(unaudited)
	Raw materials	$	13	$	13
	Work in process	4		—
	Finished goods	2		4
	Total inventory	$	19	$	17

Accrued_Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Liabilities	'
	Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
		(unaudited)
	Accrued research and development and professional services	$	1,237	$	405
	Employee compensation	197		649
	Unearned revenue	18		28
	Total accrued liabilities	$	1,452	$	1,082

Series_C_Convertible_Preferred

Series C Convertible Preferred Stock Warrant Liability	6 Months Ended
	Jun. 30, 2014
Other Liabilities Disclosure [Abstract]	'
Series C Convertible Preferred Stock Warrant Liability	'
	Series C Convertible Preferred Stock Warrant Liability
	In October 2013, pursuant to the issuance of our Series C convertible preferred stock, we issued fully exercisable warrants for the purchase of 1,975,532 shares of our Series C convertible preferred stock at an exercise price of $8.175 per share. The warrants will expire at the earlier of two years from issuance, upon certain clinical milestones or upon a liquidation event.
	All warrants were unexercised as of December 31, 2013 and June 30, 2014. The estimated fair value for the warrants as of December 31, 2013 and June 30, 2014 was $3,336,000 and $7,486,000, respectively. The fair value of the warrants was determined using the income method valuation model in combination with a Monte Carlo simulation in consideration of multiple early exercise triggers associated with the warrants.
	In April 2014, we amended the warrants to provide for their automatic net exercise if the per share price in the IPO exceeds the exercise price of the warrants, immediately prior to the closing of the IPO. In July 2014, prior to the completion of the IPO, 996,940 of the warrants were cash exercised for $8.1 million in cash and 978,592 of the warrants were automatically net exercised for a total of 311,923 shares of common stock. Upon exercise of the warrants, the preferred stock liability was reclassified from liabilities to stockholders' (deficit) equity.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Operating Leases
	In December 2013, we entered into a new operating lease agreement for office space in South San Francisco, California. The lease commenced in January 2014 and continues through January 2018, with an option to extend for an additional three years. The terms of the office lease provide for rental payments on a monthly basis and on a graduated scale. We recognize rent expense on a straight-line basis over the lease period and accrue for rent expense incurred but not paid. The lease also requires us to pay additional amounts for operating and maintenance expenses beginning January 2015. With the execution of this lease, we were required to provide a $36,000 letter of credit as a security deposit. As of June 30, 2014, no funds had been drawn down on the letter of credit.
	Contingencies
	We have potential future milestone payments to third parties as part of certain collaboration and licensing agreements, which could total up to $2.4 million in aggregate payments for the first licensed GLA product we develop, up to $1.3 million in aggregate payments for each subsequent licensed GLA product we develop and up to $1.9 million in aggregate payments for the ZVex products we develop. We also have potential future royalty payments we may be required to make under our licensing agreements as described in Note 9.
	These payments have not been recorded as liabilities due to the uncertainty of the occurrence of the events requiring payment under these agreements, including our share of potential future milestone and royalty payments. These payments generally become due and payable only upon achievement of certain clinical development, regulatory or commercial milestones.

License_and_Collaboration_Agre

License and Collaboration Agreements	6 Months Ended
	Jun. 30, 2014
Research and Development [Abstract]	'
License and Collaboration Agreements	'
	License and Collaboration Agreements
	In October 2010, we entered into three separate license agreements with MedImmune, LLC (MedImmune), pursuant to which we granted MedImmune a worldwide, sublicensable, exclusive license to use GLA to develop and sell vaccines in three different infectious disease indications. In 2010, MedImmune paid us upfront payments under the license agreements. Under each license agreement, MedImmune is obligated to make additional payments based on achievement of certain development, regulatory, and commercial milestones for the licensed indication. MedImmune is also obligated to pay us a low double-digit percentage share of non-royalty payments that it receives from sublicensees and a mid single-digit royalty payments on net sales of licensed products, which royalty is subject to reduction under certain circumstances. Through June 30, 2014, MedImmune has paid us an aggregate of $4.5 million in payments under the license agreements. Under each license agreement, MedImmune is obligated to make additional aggregate payments of $62.9 million to $76.0 million, depending on the infectious disease indication, based on achievement of certain development, regulatory and commercial milestones for the licensed indication. For the three-months ended June 30, 2014 we recognized $1.0 million for the achievement of development milestones under these license agreements.
	In May 2013, we entered into a nonexclusive license agreement granting Medicago, Inc. (Medicago) a right to research, develop, and commercialize GLA in the field of pandemic influenza. Medicago paid an upfront payment of
	$0.5 million under the license agreement, which was fully recognized in 2013, and is also obligated to make additional payments of up to $9.5 million based on achievement of certain development and government contract milestones for the licensed indication. Medicago is also obligated to pay us a mid single-digit royalty on net sales of licensed products, which royalty is subject to reduction under license expiration.
	Under our license agreement with the Infectious Disease Research Institute (IDRI), we are obligated to share with IDRI a percentage of payments received from third party licensees.
	In July 2008, we licensed certain rights to research, develop, and commercialize GLA from IDRI and amended the agreement in 2010. We paid an upfront fee and issued shares of our common stock valued at $59,000 for the license. In addition, we agreed to pay certain fees in the future if we should elect to continue development of the applicable technologies, including milestone payments upon achievement of certain development and commercialization milestones and royalty payments of single-digit percentage of net sales, if and when commercialized; however, we may terminate our development programs at any time without obligation to IDRI.
	Through June 30, 2014, we have paid an aggregate of $1.4 million in upfront fees, milestone payments and sublicense revenue related to our sublicensees. We expensed these amounts to research and development expense, as the rights had no alternative future use. In 2013, we paid $140,000 in license-related milestone payments which were expensed in research and development expenses. We are obligated to pay IDRI up to $2.4 million in additional payments based on the achievement of certain developmental and regulatory milestones for the first GLA product, and up to $1.3 million in additional payments based on the achievement of certain developmental and regulatory milestones for each subsequent GLA product.
	In January 2009, we licensed certain patent rights directed to the production of dendritic cell-targeted therapeutic and prophylactic immunization strategies from the California Institute of Technology (Caltech). In 2009, we issued shares of our common stock valued at $25,000 for this license. We have made annual minimum royalty payments under the license annually through January 2014. In addition, we agreed to pay certain fees in the future if we should elect to continue development of the related technology, including milestone payments upon achievement of certain development and commercialization milestones and royalty payments on net sales, if and when commercialized, in the low single digit percentage; however, we may terminate our development program at any time without further obligation to Caltech. In addition, we are required to pay Caltech up to an aggregate of $1.6 million in additional payments upon the achievement of certain regulatory and sales milestones.

Stockholders_Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Deficit	'
	Stockholders’ Deficit
	Common Stock
	We had 369,750 and 369,460 shares of common stock outstanding as of June 30, 2014 and December 31, 2013 respectively. Shares of common stock reserved for future issuance were as follows:
		June 30,			December 31,
		2014			2013
		(unaudited)
	Shares to be issued upon conversion of convertible preferred stock	9,769,422			9,769,422
	Shares to be issued upon exercise of convertible preferred stock warrants and conversion of convertible preferred stock	1,975,532			1,975,532
	Shares to be issued upon exercise of outstanding stock options	1,802,626			1,463,747
	Shares available for future stock option grants	77,240			122,829
	Shares of common stock reserved for future issuance	13,624,820			13,331,530
	Equity Incentive Plan
	In 2008, we adopted the 2008 Equity Incentive Plan (2008 Plan) for eligible employees, officers, directors, and consultants, which provides for the grant of incentive and non-statutory stock options, restricted stock awards, restructured stock unit awards grant, and stock appreciation rights. The terms of the stock awards, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2008 Plan.
	Stock options granted under the 2008 Plan generally vest within four years and vested options are exercisable from the grant date until ten years after the date of grant. Vesting of certain employee options may be accelerated in the event of a change in control of our company. We grant stock options to employees with exercise prices equal to the fair value of our common stock on the date of grant. The term of incentive stock options may not exceed ten years from the date of grant. In May 2014, an additional 293,576 shares of common stock were authorized for future grants under the 2008 Plan. There were 1,951,514 shares of common stock authorized under the 2008 Plan as of June 30, 2014.
	In April 2014, our board of directors adopted, and in July 2014 our stockholders approved, the 2014 Omnibus Incentive Plan (2014 Plan) which provides for the granting of certain awards to eligible employees, officers, directors, and consultants. Upon approval of the 2014 Plan, we ceased granting stock awards under the 2008 Plan, and any shares of common stock subject to awards under the 2008 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued will become available for issuance under the 2014 Plan.
	Stock Option Activity
	Summary stock option information is as follows:
		OPTIONS			WEIGHTED-				WEIGHTED-		AGGREGATE
		OUTSTANDING			AVERAGE				AVERAGE		INTRINSIC
					EXERCISE				REMAINING		VALUE
					PRICE				CONTRACT		(IN THOUSANDS)
									TERM
									(IN YEARS)
	Outstanding at December 31, 2013	1,463,747			$	1.2			8.67		$	2,552
	Granted (unaudited)	370,604			$	8.49
	Exercised (unaudited)	(290	)		$	1.31
	Canceled/forfeited (unaudited)	(31,435	)		$	1.82
	Outstanding at June 30, 2014 (unaudited)	1,802,626			$	2.69			8.51		$	11,215
	Vested and expected to vest after June 30, 2014 (unaudited)	1,460,814			$	2.4			8.27		$	9,505
	Exercisable as of June 30, 2014 (unaudited)	551,028			$	1.11			6.56		$	4,300
	As of June 30, 2014, there was $2.7 million of total unrecognized stock-based compensation expense related to nonvested stock options that is expected to be recognized over a weighted-average period of 3.2 years.
	Stock-Based Compensation Expense
	Employee stock-based compensation expense recognized was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. Total stock-based compensation expense recognized in our accompanying statements of operations is as follows (in thousands):
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
		(unaudited)
	Employee:
	Research and development	$	92			$	8			$	143		$	16
	General and administrative	143				26				229			49
	Non-Employee:
	Research and development	32				(3		)		82			1
	General and administrative	—				7				—			18
	Total stock-based compensation expense	$	267			$	38			$	454		$	84
	We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model requires us to make certain estimates and assumptions, including assumptions related to the expected price volatility of our stock, the period during which the options will be outstanding, the rate of return on risk-free investments, and the expected dividend yield of our stock. The fair values of stock options granted to employees were calculated using the following assumptions:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
		(unaudited)
	Weighted-average estimated fair value	$6.33		$1.09		$6.33		1.08
	Risk-free interest rate	1.76% - 2.16%		1.16% - 1.22%		1.76% - 2.16%		0.97% - 1.22%
	Expected term of options (in years)	5.50 - 6.75		5.97 - 6.01		5.50 - 6.75		5.45 - 6.08
	Expected stock price volatility	90%		90%		90%		90%
	Expected dividend yield	—%		—%		—%		—%
	We used the “simplified method” for options to determine the expected term of our stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. Volatility is a measure of the amount by which a financial variable, such as share price, has fluctuated or is expected to fluctuate during a period. We analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price. The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of our stock option grants. We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable.

Legal_Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Legal Proceedings	'
	Legal Proceedings
	TheraVectys
	TheraVectys SA v. Henogen SA
	In September 2013, TheraVectys SA, or (TVS), a French biotechnology company, filed an action in the Commercial Court of Charleroi in Belgium against Henogen SA (Henogen). Henogen is a contract manufacturing organization with which we contracted for the manufacture of our LV305 product candidate. We were not named as a defendant in the action. In this action, TVS alleged that Henogen was preparing to transfer TVS’s proprietary and to us by dispatching batches of our lentiviral vector and was acting in breach of an alleged exclusivity obligation towards TVS. On September 11, 2013, Henogen was served with an ex parte order of the Commercial Court of Charleroi temporarily enjoining Henogen from manufacturing, dispatching, delivering or communicating about batches of lentiviral vectors to any company or individual other than TVS. On September 18, 2013, Henogen filed an opposition to the ex parte order, and, in a hearing on September 19, 2013, requested the annulment of the ex parte order. We filed an application to intervene and our counsel appeared at the hearing in support of Henogen’s request to annul the ex parte order. On October 7, 2013, the Commercial Court of Charleroi issued an order extending the temporary injunction by an additional 15-day period starting on the date of the serving of the judgment by the most diligent party but allowing it to terminate thereafter. We believe the time to appeal that order has expired.
	TheraVectys SA v. Immune Design Corp.
	In October 2013, TVS filed a complaint against us in the U.S. District Court for the District of Delaware. TVS alleged that it had entered into a contractual relationship with Henogen in 2010 with respect to the production of lentiviral vector vaccines for TVS. TVS alleged that the contractual relationship with Henogen contained an exclusivity provision limiting Henogen’s ability to participate in the manufacturing process of a vaccine based on lentiviral DNA Flap vectors for third parties and a provision preventing Henogen from sharing or using certain TVS confidential technology for manufacturing processes developed by TVS with or for the benefit of others. TVS alleged that we entered into a contractual relationship with Henogen in 2012 to manufacture lentiviral vectors for vaccines, which TVS contends interfered with its contract with Henogen and resulted in the use of certain TVS confidential information and trade secrets. The complaint asserted three counts for relief: tortious interference with contractual relationship, unfair competition and misappropriation of trade secrets. TVS did not specify its claimed damages, other than to assert that they exceed $75,000. TVS also requested injunctive relief enjoining us from importing, receiving possessing or using lentiviral vector vaccines developed or produced by Henogen, but did not file a motion seeking that relief. The parties entered into several stipulations extending the deadline for us to respond to the complaint. On or about April 7, 2014, TVS filed a Notice of Voluntary Dismissal without prejudice of this lawsuit.
	Henogen SA v. TheraVectys SA
	In October 2013, Henogen filed an action in the Paris Commercial Court against TVS. We were not a party to this action. The action sought declarations that the provisions of the contract between Henogen and TVS upon which TVS in part based its claims in the Commercial Court of Charleroi is either null or does not apply to Henogen’s contract with us, that Henogen has not engaged in an act of unfair competition and that TVS wrongfully obtained an order of the Commercial Court of Charleroi in Belgium temporarily enjoining Henogen from manufacturing, dispatching, delivering or communicating about batches of lentiviral vectors to any company or individual other than TVS based on unfounded allegations. The action also sought damages, publication of the Paris Commercial Court’s judgment in Belgian and French national newspapers at TVS’s expense, and an order forbidding TVS from initiating any action that could prevent the performance of the contract between Henogen and us for the manufacture of our lentiviral vector. Henogen also requested the Court to appoint an expert to describe the know-how of Henogen prior to its collaboration with TVS and the know-how transferred by us to Henogen and the know-how transferred by TVS to Henogen. TVS requested that the Commercial Court of Paris order Henogen to cease working with us and pay damages to TVS. TVS opposed the appointment of an expert. The Commercial Court of Paris heard arguments from Henogen and TVS at a hearing on March 7, 2014. The Commercial Court of Paris rendered a decision on April 11, 2014. In that decision, the court dismissed all claims raised by Henogen and declined its request for the appointment of an expert. The court determined that Henogen had breached the agreement with TVS and, among other things, ordered Henogen to pay TVS €15,000,000 in compensatory damages, €100,000 for initiating abusive proceedings, €150,000 for legal fees as well as an award for court costs incurred in the matter. The court ordered provisional enforcement of the judgment. On April 14, 2014, Henogen filed an appeal against the judgment and filed summary proceedings to suspend the provisional execution of the judgment. In June 2014, Henogen’s request to suspend the provisional judgment was denied.
	European Patent Opposition
	In February 2013, a third party filed an opposition at the European Patent Office, or EPO, requesting revocation of European Patent No. 2068918 directed to GLA formulations and uses. This patent is owned by IDRI and under license to us. We are vigorously defending the grant of this patent, with a reply to the opposition brief having been filed on September 27, 2013. No date for an oral hearing has yet been set. This patent is an important part of our proprietary position for GLA in Europe. The final outcome of the proceedings is uncertain and will likely not be known for two to five years.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	Initial Public Offering
	On July 23, 2014, our registration statements on Form S-1 (File No. 333-196979) relating to our IPO of common stock became effective. The IPO closed on July 29, 2014 at which time we sold 5,000,000 shares of our common stock. On August 1, 2014, we sold an additional 250,000 shares of our common stock directly to the underwriters when they partially exercised their over-allotment option. On August 26, 2014, we sold an additional 160,564 shares of our common stock directly to the underwriters when they again partially exercised their over-allotment option. We sold an aggregate of 5,410,564 shares of our common stock in the IPO and received cash proceeds of $60.4 million from the IPO, net of underwriting discounts and commissions and expenses paid by us.
	Upon completion of the IPO the total authorized common stock was increased to 100,000,000 and the total authorized preferred stock was increased to 10,000,000.
	Stock Option Plan
	In July 2014 our stockholders approved, the 2014 Omnibus Incentive Plan (2014 Plan) which provides for the granting of certain awards to eligible employees, officers, directors, and consultants. Upon approval of the 2014 Plan, we will cease granting stock awards under the 2008 Plan, and any shares of common stock subject to awards under the 2008 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued will become available for issuance under the 2014 Plan.
	In July 2014, 1,400,000 shares of our common stock were reserved for issuance under the 2014 Plan and 155,520 shares of our common stock were reserved for issuance under our 2014 Employee Stock Purchase Plan, which became effective immediately prior to the closing of the IPO.
	Reverse Stock Split
	On July 14, 2014, the Company filed an amendment to its amended and restated certificate of incorporation, effecting a 1-for-8.175 reverse stock split. All issued and outstanding stock and per share amounts contained in our financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.
	License Agreements
	In August 2014, we entered into a license agreement with Sanofi for use of our GLAAS discovery platform to develop therapeutic agents to treat a selected food allergy. Under terms of the agreement, we granted Sanofi an exclusive license to discover, develop and commercialize products to treat the selected food allergy, and in addition to an undisclosed upfront payment, we will be eligible to receive development and commercialization milestones totaling $168.0 million and tiered royalties on sales of approved products.
	TheraVectys SA v. Immune Design Corp.
	On or about July 24, 2014, shortly after our Registration Statement on Form S-1 was declared effective by the SEC, TVS filed a new complaint against us in the Chancery Court of the State of Delaware, alleging facts substantially similar to the prior complaint. TVS has alleged in the new complaint facts substantially similar to the prior complaint. In addition, the complaint further alleges that we obtained shipments of lentiviral vectors for vaccines from Henogen and are conducting clinical trials with these lentiviral vectors. The complaint asserts four counts for relief: tortious interference with contractual relationship, unfair competition, misappropriation of trade secrets, and unjust enrichment; claimed damages are not specified. The complaint also requested injunctive relief enjoining us from using lentiviral vectors developed or produced by Henogen, using any other materials or information obtained by Henogen, and citing to the U.S. Food and Drug Administration (FDA) or otherwise relying on any clinical trials using lentiviral vector vaccines developed or produced by Henogen.
	On or about July 24, 2014, TVS also filed a motion for expedited proceedings in support of an anticipated motion for preliminary injunction. On August 8, 2014 the court held that the proceedings should be expedited and set a hearing date in mid-November 2014 for Thervectys’s anticipated motion for preliminary injunction. The court has not yet made any determination on the merits of the suit
	We are not currently using Henogen to manufacture our lentiviral vectors for our clinical trials. We developed our own vector manufacturing process that was then transferred to Henogen, and did not have any knowledge of the exclusivity provision in TVS’ contract with Henogen or its manufacturing processes when we entered into our agreement with Henogen. We intend to vigorously defend this lawsuit. In the event we are unable to use any of our lentiviral vectors or the clinical data from the ongoing Phase 1 trial of LV305 as a result of an injunction ordered by the Delaware Chancery Court, the development of LV305 could be substantially delayed and our business could be harmed. In addition, an adverse outcome could result in the payment of damages by us to TVS, which could have a material adverse effect on our cash flows, financial position and results of operations.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Use of Estimates	'
	Basis of Presentation and Use of Estimates
	The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). To conform with GAAP, the preparation of our financial statements requires management to make judgments, assumptions, and estimates that affect the amounts reported in our financial statements and accompanying notes. Estimates are used for, but not limited to, accruals for clinical trial activity, other accrued liabilities, and assumptions used in determining stock-based compensation expenses and convertible preferred stock warrant liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ materially from those estimates.
Segments	'
	Segments
	We operate in one segment and use cash flow as the primary measure to manage our business and do not segment the business for internal reporting or decision-making purposes.
Reverse Stock Split and Initial Public Offering	'
	Reverse Stock Split
	On July 14, 2014, we filed an amendment to our amended and restated certificate of incorporation, effecting a 1-for-8.175 reverse stock split. All issued and outstanding stock and per share amounts contained in our financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.
	Initial Public Offering
	In July 2014, we completed our initial public offering of shares of our common stock (IPO), pursuant to which we issued 5,000,000 shares of our common stock, at a price of $12.00 per share. In August 2014, we sold an additional 410,564 shares of common stock directly to our underwriters when they exercised a portion of their over-allotment at $12.00 per share. We received net proceeds of $60.4 million (inclusive of the exercise of the over-allotment) after deducting underwriting discounts and commissions and offering expenses from the IPO. In connection with the closing of the IPO, all of our outstanding shares of convertible preferred stock automatically converted into 9,769,422 shares of common stock. In July 2014, prior to the completion of the IPO, warrants to purchase 996,940 shares were cash exercised for $8.1 million and resulted in the issuance of an additional 996,940 shares of common stock. Immediately prior to the closing of the IPO, warrants to purchase 978,592 shares were automatically net exercised, resulting in an issuance of an additional 311,923 shares of common stock. The significant increase in shares outstanding in July 2014 is expected to impact the year-over-year comparability of our net loss per share calculations over the next year.
Deferred Offering Costs	'
	Deferred Offering Costs
	Deferred offering costs represent legal, accounting and other direct costs related to our efforts to raise capital through our IPO of our common stock. These costs were deferred through the completion of the IPO and on the completion of the IPO will be reclassified to additional paid-in capital as a reduction of the proceeds.
Comprehensive Loss	'
	Comprehensive Loss
	Comprehensive loss is comprised of net loss and certain changes in equity that are excluded from net loss. There was no difference between comprehensive loss and net loss for the three and six months ended June 30, 2014 and 2013.
Revenue Recognition	'
	Revenue Recognition
	We derive our revenue from collaboration and licensing agreements and the sale of products associated with material transfer, collaboration and supply agreements.
	Licensing fees are recognized when the amounts are earned and determinable during the applicable period. We recognize up-front nonrefundable license fees when due under contractual agreements and when we do not have a continuing obligation to provide services related to the agreement. Revenue associated with nonrefundable up-front license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected term of our continued involvement in the research and development process. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, we recognize such milestones as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process.
	Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable, (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. Payments received in advance of work performed are recorded as deferred revenue.
	Certain agreements from which we derive our revenue include multiple deliverables. We recognize the revenue for each deliverable at fair value determined to be estimated selling price in cases when neither vendor specific objective evidence nor third-party evidence is available.
	Revenue is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price to the customer is fixed or determinable; and (4) collectability is reasonably assured. The evaluation of these revenue recognition criteria requires significant management judgment. For instance, we use judgment to assess collectability based on factors such as the customer’s creditworthiness and past collection history, if applicable. If we determine that collection of a payment is not reasonably assured, revenue recognition is deferred until receipt of payment. We also use judgment to assess whether a price is fixed or determinable including, but not limited to, reviewing contractual terms and conditions related to payment terms.
	Revenue from product sales of glucopyranosyl lipid A (GLA), is recognized when the risk of loss has passed to the customer or deferred until such time that risk of loss has passed. All revenues associated from the sale of GLA products supplied by us are reported under product sales with the applicable costs reported under cost of product sales. Product sales consist of the direct costs associated with the manufacture and formulation of GLA, including costs to purchase raw materials, third-party contract manufacturing costs, assay testing and ongoing product stability testing.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB), issued Accounting Standards Update (ASU) No. 2014-09, related to the recognition of revenue. The standard requires entities to recognize revenue through the application of a five step model, which includes identification of the contract, identification of the performance obligations, determination of the transaction price, allocation of the transaction price to the performance obligations, and recognition of revenue as the entity satisfies the performance obligations. ASU 2014-09 is effective retrospectively for annual or interim reporting periods beginning after December 15, 2016, with early application not permitted. We are evaluating the guidance to determine the potential impact on our results of operations, financial condition, cash flows, and financial statement disclosures.

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Common Stock Issuable Upon the Conversion or Exercise of Dilutive Securities Excluded from Diluted Net Loss Per Share Attributable to Common Stockholders	'
	The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share attributable to common stockholders calculation because their effect would have been antidilutive for the periods presented:
		Three Months Ended June 30,
		2014	2013
		(unaudited)
	Convertible preferred stock	9,769,422	5,818,356
	Options to purchase common stock	1,802,626	732,445
	Warrants to purchase convertible preferred stock	1,975,532	—
		13,547,580	6,550,801

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis (in thousands):
			30-Jun-14
			(unaudited)
			LEVEL 1		LEVEL 2		LEVEL 3		TOTAL
	Assets:
	Money market funds		$	17,716	$	—	$	—	$	17,716
	Liabilities:
	Convertible preferred stock warrant liability		$	—	$	—	$	7,486	$	7,486
			31-Dec-13
			LEVEL 1		LEVEL 2		LEVEL 3		TOTAL
	Assets:
	Money market funds		$	30,030	$	—	$	—	$	30,030
	Liabilities:
	Convertible preferred stock warrant liability		$	—	$	—	$	3,336	$	3,336
Reconciliation of Convertible Preferred Stock Warranty Liability Measured and Recorded at Fair Value on a Recurring Basis	'
	The table below shows the reconciliation of the convertible preferred stock warrant liability measured and recorded at fair value on a recurring basis, using significant unobservable inputs (Level 3) (in thousands):
		Estimated Fair Value
	Balance as of December 31, 2013	$	3,336
	Change in fair value of convertible preferred stock warrant liability (unaudited)	4,150
	Balance as of June 30, 2014 (unaudited)	$	7,486

Inventory_Tables

Inventory (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventory consists of the following (in thousands):
		June 30,		December 31,
		2014		2013
		(unaudited)
	Raw materials	$	13	$	13
	Work in process	4		—
	Finished goods	2		4
	Total inventory	$	19	$	17

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued liabilities consist of the following (in thousands):
		June 30,		December 31,
		2014		2013
		(unaudited)
	Accrued research and development and professional services	$	1,237	$	405
	Employee compensation	197		649
	Unearned revenue	18		28
	Total accrued liabilities	$	1,452	$	1,082

Stockholders_Deficit_Tables

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Schedule of Shares of Common Stock Reserved for Future Issuance	'
	Shares of common stock reserved for future issuance were as follows:
		June 30,			December 31,
		2014			2013
		(unaudited)
	Shares to be issued upon conversion of convertible preferred stock	9,769,422			9,769,422
	Shares to be issued upon exercise of convertible preferred stock warrants and conversion of convertible preferred stock	1,975,532			1,975,532
	Shares to be issued upon exercise of outstanding stock options	1,802,626			1,463,747
	Shares available for future stock option grants	77,240			122,829
	Shares of common stock reserved for future issuance	13,624,820			13,331,530
Summary of Stock Options	'
	Summary stock option information is as follows:
		OPTIONS			WEIGHTED-				WEIGHTED-		AGGREGATE
		OUTSTANDING			AVERAGE				AVERAGE		INTRINSIC
					EXERCISE				REMAINING		VALUE
					PRICE				CONTRACT		(IN THOUSANDS)
									TERM
									(IN YEARS)
	Outstanding at December 31, 2013	1,463,747			$	1.2			8.67		$	2,552
	Granted (unaudited)	370,604			$	8.49
	Exercised (unaudited)	(290	)		$	1.31
	Canceled/forfeited (unaudited)	(31,435	)		$	1.82
	Outstanding at June 30, 2014 (unaudited)	1,802,626			$	2.69			8.51		$	11,215
	Vested and expected to vest after June 30, 2014 (unaudited)	1,460,814			$	2.4			8.27		$	9,505
	Exercisable as of June 30, 2014 (unaudited)	551,028			$	1.11			6.56		$	4,300
Schedule of Stock-Based Compensation Expense Recognized	'
	Total stock-based compensation expense recognized in our accompanying statements of operations is as follows (in thousands):
		Three Months Ended June 30,								Six Months Ended June 30,
		2014				2013				2014			2013
		(unaudited)
	Employee:
	Research and development	$	92			$	8			$	143		$	16
	General and administrative	143				26				229			49
	Non-Employee:
	Research and development	32				(3		)		82			1
	General and administrative	—				7				—			18
	Total stock-based compensation expense	$	267			$	38			$	454		$	84
Schedule of Fair Value of Stock Options Granted to Employees	'
	The fair values of stock options granted to employees were calculated using the following assumptions:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
		(unaudited)
	Weighted-average estimated fair value	$6.33		$1.09		$6.33		1.08
	Risk-free interest rate	1.76% - 2.16%		1.16% - 1.22%		1.76% - 2.16%		0.97% - 1.22%
	Expected term of options (in years)	5.50 - 6.75		5.97 - 6.01		5.50 - 6.75		5.45 - 6.08
	Expected stock price volatility	90%		90%		90%		90%
	Expected dividend yield	—%		—%		—%		—%

Description_of_the_Business_Na

Description of the Business - Narrative (Details)	6 Months Ended
	Jun. 30, 2014
	platform
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of discovery platforms	2

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Segments (Details)	6 Months Ended
	Jun. 30, 2014
	segment
Accounting Policies [Abstract]	'
Number of operating segments	1

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Reverse Stock Split (Details) (Subsequent Event [Member])	0 Months Ended
	Jul. 14, 2014
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Reverse stock split ratio	0.122324159

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Initial Public Offering (Details) (Subsequent Event [Member], USD $)	1 Months Ended		0 Months Ended	1 Months Ended	0 Months Ended		1 Months Ended
In Millions, except Share data, unless otherwise specified	Aug. 31, 2014	Aug. 26, 2014	Jul. 29, 2014	Jul. 31, 2014	Aug. 26, 2014	Aug. 01, 2014	Aug. 31, 2014	Jul. 31, 2014	Jul. 31, 2014	Jul. 31, 2014
	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Convertible Preferred Stock, Series C [Member]	Warrant [Member]
			IPO [Member]	IPO [Member]	Over-Allotment Option [Member]	Over-Allotment Option [Member]	Over-Allotment Option [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of common stock sold in IPO (in shares)	'	5,410,564	5,000,000	5,000,000	160,564	250,000	410,564	311,923	'	996,940
Share price (in USD per share)	'	'	'	$12	'	'	$12	'	'	'
Net proceeds	$60.40	$60.40	'	'	'	'	'	'	'	'
Number of convertible preferred stock converted to common stock (in shares)	'	'	'	9,769,422	'	'	'	'	'	'
Proceeds from warrants exercised	'	'	'	'	'	'	'	'	$8.10	'
Warrants exercised in period (in shares)	'	'	'	'	'	'	'	978,592	996,940	'

Net_Loss_Per_Share_Common_Stoc

Net Loss Per Share - Common Stock Issuable Upon the Conversion or Exercise of Dilutive Securities Excluded from Diluted Net Loss Per Share Attributable to Common Stockholders (Details)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	13,547,580	6,550,801
Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	9,769,422	5,818,356
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	1,802,626	732,445
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	1,975,532	0

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible preferred stock warrant liability	$7,486	$3,336
Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Money market funds	17,716	30,030
Convertible preferred stock warrant liability	7,486	3,336
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Money market funds	17,716	30,030
Convertible preferred stock warrant liability	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Money market funds	0	0
Convertible preferred stock warrant liability	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Money market funds	0	0
Convertible preferred stock warrant liability	$7,486	$3,336

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Reconciliation of Convertible Preferred Stock Warranty Liability Measured and Recorded at Fair Value on a Recurring Basis (Details) (Preferred Stock Warrant Liability [Member], USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Preferred Stock Warrant Liability [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Beginning balance	$3,336
Change in fair value of convertible preferred stock warrant liability (unaudited)	4,150
Ending balance	$7,486

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Narrative (Details) (Preferred Stock Warrant Liability [Member])	1 Months Ended	6 Months Ended	12 Months Ended
	Oct. 31, 2013	Jun. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Volatility rate	82.00%	102.30%	82.00%
Risk free interest rate	0.30%	0.20%	0.30%
Minimum [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Time to maturity	'1 year 8 months 14 days	'0 years 0 months 21 days	'1 year 2 months 29 days
Maximum [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Time to maturity	'1 year 11 months 21 days	'1 year 3 months 0 days	'1 year 8 months 28 days

Inventory_Details

Inventory (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$13	$13
Work in process	4	0
Finished goods	2	4
Total inventory	$19	$17

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accrued research and development and professional services	$1,237	$405
Employee compensation	197	649
Unearned revenue	18	28
Total accrued liabilities	$1,452	$1,082

Series_C_Convertible_Preferred1

Series C Convertible Preferred Stock Warrant Liability (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Oct. 31, 2013	Jul. 31, 2014	Jul. 31, 2014
			Convertible Preferred Stock, Series C [Member]	Convertible Preferred Stock, Series C [Member]	Common Stock [Member]
				Subsequent Event [Member]	Subsequent Event [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'
Number of warrants exercisable (in shares)	'	'	1,975,532	'	'
Warrant exercise price (in USD per share)	'	'	$8.18	'	'
Warrant expiration period	'	'	'2 years	'	'
Fair value of warrants outstanding	$7,486,000	$3,336,000	'	'	'
Proceeds from warrants exercised	'	'	'	$8,100,000	'
Warrants exercised in period (in shares)	'	'	'	996,940	978,592
Additional shares of common stock issued (in shares)	'	'	'	'	311,923

Commitments_and_Contingencies_

Commitments and Contingencies - Narrative (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
		Financial Standby Letter of Credit [Member]	Collaborative Arrangement [Member]	Collaborative Arrangement [Member]	Collaborative Arrangement [Member]
			ZVex Product [Member]	Infectious Disease Research Institute [Member]	Infectious Disease Research Institute [Member]
				First GLA Product [Member]	Subsequent GLA Products [Member]
Other Commitments [Line Items]	'	'	'	'	'
Optional lease extension period	'3 years	'	'	'	'
Letter of credit provided as security deposit	'	$36,000	'	'	'
Funds drawn on letter of credit	0	'	'	'	'
Potential future milestone payments	'	'	$1,900,000	$2,400,000	$1,300,000

License_and_Collaboration_Agre1

License and Collaboration Agreements - Narrative (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

45 Months Ended

8 Months Ended

12 Months Ended

72 Months Ended

1 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Oct. 31, 2010

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jul. 31, 2008

Jun. 30, 2014

Jun. 30, 2014

Jan. 31, 2009

Jun. 30, 2014

GLA [Member]

GLA [Member]

GLA [Member]

GLA [Member]

GLA [Member]

GLA [Member]

GLA [Member]

GLA [Member]

GLA [Member]

GLA [Member]

First GLA Product [Member]

Subsequent GLA Products [Member]

Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies [Member]

Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

Collaborative Arrangement [Member]

MedImmune LLC [Member]

MedImmune LLC [Member]

MedImmune LLC [Member]

MedImmune LLC [Member]

MedImmune LLC [Member]

Medicago Inc [Member]

Medicago Inc [Member]

Infectious Disease Research Institute [Member]

Infectious Disease Research Institute [Member]

Infectious Disease Research Institute [Member]

Infectious Disease Research Institute [Member]

Infectious Disease Research Institute [Member]

California Institute of Technology [Member]

California Institute of Technology [Member]

license_agreement

Minimum [Member]

Maximum [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of license agreements

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

Milestone revenue recognized

'

'

'

'

$1,000,000

$4,500,000

'

'

'

$500,000

'

'

'

'

'

'

'

'

Milestone receivables

'

'

'

'

'

'

'

62,900,000

76,000,000

'

9,500,000

'

'

'

'

'

'

'

Value of common stock issued for license

'

'

'

'

'

'

'

'

'

'

'

'

'

59,000

'

'

25,000

'

Research and development

3,883,000

3,356,000

7,961,000

5,899,000

'

'

'

'

'

'

'

140,000

1,400,000

'

'

'

'

'

Potential future milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,400,000

$1,300,000

'

$1,600,000

Stockholders_Deficit_Schedule_

Stockholders' Deficit - Schedule of Shares of Common Stock Reserved for Future Issuance (Details)	Jun. 30, 2014	Dec. 31, 2013
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	13,624,820	13,331,530
Stock Options Outstanding [Member]	'	'
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	1,802,626	1,463,747
Future Stock Grants [Member]	'	'
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	77,240	122,829
Convertible Preferred Stock Warrants and Convertible Preferred Stock [Member]	'	'
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	1,975,532	1,975,532
Convertible Preferred Stock Warrants and Convertible Preferred Stock [Member]	'	'
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	9,769,422	9,769,422

Stockholders_Deficit_Summary_o

Stockholders' Deficit - Summary of Stock Options (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Options outstanding, Beginning balance (in shares)	1,463,747	'
Options granted in period (in shares)	370,604	'
Options exercised in period (in shares)	-290	'
Options cancelled in period (in shares)	-31,435	'
Options outstanding, Ending balance (in shares)	1,802,626	1,463,747
Options vested and expected to vest after June 30, 2014 (in shares)	1,460,814	'
Exercisable options as of June 30, 2014 (in shares)	551,028	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]	'	'
Weighted average exercise price, Beginning balance (in USD per share)	$1.20	'
Weighted average exercise price of options granted in period (in USD per share)	$8.49	'
Weighted average exercise price of options exercised in period (in USD per share)	$1.31	'
Weighted average exercise price of options cancelled in period (in USD per share)	$1.82	'
Weighted average exercise price, Ending balance (in USD per share)	$2.69	$1.20
Weighted average exercise price of options vested and expected to vest after June 30, 2014 (in USD per share)	$2.40	'
Weighted average exercise price of exercisable options as of June 30, 2014 (in USD per share)	$1.11	'
Weighted average remaining contract term for outstanding options, Beginning	'8 years 6 months 3 days	'8 years 8 months 1 day
Weighted average remaining contract term for options vested and expected to vest after June 30, 2014	'8 years 3 months 7 days	'
Weighted average remaining contract term for exercisable options as of June 30, 2014	'6 years 6 months 21 days	'
Aggregate intrinsic value, Beginning balance	$11,215	$2,552
Aggregate intrinsic value of options vested and expected to vest after June 30, 2014	9,505	'
Aggregate intrinsic value of exercisable options as of June 30, 2014	$4,300	'

Stockholders_Deficit_Schedule_1

Stockholders' Deficit - Schedule of Stock-Based Compensation Expense Recognized (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Employee share-based compensation expense	$267	$38	$454	$84
Employee [Member] | Research and Development Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Employee share-based compensation expense	92	8	143	16
Employee [Member] | General and Administrative Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Employee share-based compensation expense	143	26	229	49
Non-Employee [Member] | Research and Development Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Employee share-based compensation expense	32	-3	82	1
Non-Employee [Member] | General and Administrative Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Employee share-based compensation expense	$0	$7	$0	$18

Stockholders_Deficit_Schedule_2

Stockholders' Deficit - Schedule of Fair Value of Stock Options Granted to Employees (Details) (Employee Stock Option [Member], USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted-average estimated fair value	$6.33	$1.09	$6.33	$1.08
Risk-free interest rate min	1.76%	1.16%	1.76%	0.97%
Risk-free interest rate max	2.16%	1.22%	2.16%	1.22%
Expected stock price volatility	90.00%	90.00%	90.00%	90.00%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Time to maturity	'5 years 6 months 0 days	'5 years 11 months 19 days	'5 years 6 months 0 days	'5 years 5 months 12 days
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Time to maturity	'6 years 9 months 0 days	'6 years 0 months 3 days	'6 years 9 months 0 days	'6 years 0 months 29 days

Stockholders_Deficit_Narrative

Stockholders' Deficit - Narrative (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	31-May-14	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
In Millions, except Share data, unless otherwise specified			2008 Equity Incentive Plan [Member]	2008 Equity Incentive Plan [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]
						2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Shares outstanding (in shares)	369,750	369,460	'	'	'	'
Vesting term	'	'	'	'	'	'4 years
Option expiration period	'	'	'	'	'	'10 years
Common stock reserved for future issuance (in shares)	'	'	293,576	'	'	'
Common stock authorized (in shares)	'	'	'	1,951,514	'	'
Unrecognized stock based compensation expense	'	'	'	'	$2.70	'
Weighted average recognition period for stock-based compensation expense	'	'	'	'	'3 years 2 months 4 days	'

Legal_Proceedings_Narrative_De

Legal Proceedings - Narrative (Details)	0 Months Ended	1 Months Ended		6 Months Ended		1 Months Ended
	Oct. 07, 2013	Oct. 31, 2013	Oct. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2013
	TheraVectys SA v. Henogen SA [Member]	Voluntarily Dismissed Litigation [Member]	Voluntarily Dismissed Litigation [Member]	Pending Litigation [Member]	Pending Litigation [Member]	Henogen SA [Member]	Henogen SA [Member]	Henogen SA [Member]
		TheraVectys SA v. Immune Design Corp. [Member]	Minimum [Member]	Minimum [Member]	Maximum [Member]	TheraVectys SA [Member]	TheraVectys SA [Member]	TheraVectys SA [Member]
		claim	TheraVectys SA v. Immune Design Corp. [Member]	Third Party Opposition at European Patent Office [Member]	Third Party Opposition at European Patent Office [Member]	Compensatory Damages [Member]	Abusive Proceedings [Member]	Legal Fees [Member]
			USD ($)			Henogen SA v. TheraVectys SA [Member]	Henogen SA v. TheraVectys SA [Member]	Henogen SA v. TheraVectys SA [Member]
						EUR (€)	EUR (€)	EUR (€)
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'
Injunction extension period	'15 days	'	'	'	'	'	'	'
Dismissed claims	'	3	'	'	'	'	'	'
Estimated damages by TVS	'	'	$75,000	'	'	'	'	'
Damages paid by Henogen to TheraVectys	'	'	'	'	'	€ 15,000,000	€ 100,000	€ 150,000
Period of outcome of EPO proceedings	'	'	'	'2 years	'5 years	'	'	'

Subsequent_Events_Narrative_De

Subsequent Events - Narrative (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Jul. 14, 2014

Jul. 29, 2014

Jul. 31, 2014

Jul. 31, 2014

Aug. 31, 2014

Aug. 26, 2014

Jul. 29, 2014

Jul. 31, 2014

Aug. 26, 2014

Aug. 01, 2014

Aug. 31, 2014

Aug. 31, 2014

Jul. 24, 2014

In Millions, except Share data, unless otherwise specified

Subsequent Event [Member]

Subsequent Event [Member]

2014 Plan [Member]

2014 Employee Stock Purchase Plan [Member]

Common Stock [Member]

Common Stock [Member]

IPO [Member]

IPO [Member]

Over-Allotment Option [Member]

Over-Allotment Option [Member]

Over-Allotment Option [Member]

Sanofi [Member]

Pending Litigation [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

GLAAS Discovery Platform [Member]

TheraVectys SA v. Immune Design Corp. [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Collaborative Arrangement, Product [Member]

Subsequent Event [Member]

Subsequent Event [Member]

claim

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock sold in IPO (in shares)

'

'

'

'

'

'

'

5,410,564

5,000,000

5,000,000

160,564

250,000

410,564

'

'

Net proceeds

'

'

'

'

'

'

$60.40

$60.40

'

'

'

'

'

'

'

Common stock authorized (in shares)

15,045,871

15,045,871

'

100,000,000

'

'

'

'

'

'

'

'

'

'

'

Preferred stock authorized (in shares)

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for future issuance (in shares)

13,624,820

13,331,530

'

'

1,400,000

155,520

'

'

'

'

'

'

'

'

'

Reverse stock split ratio

'

'

0.122324159

'

'

'

'

'

'

'

'

'

'

'

'

Milestone receivables

'

'

'

'

'

'

'

'

'

'

'

'

'

$168

'

Dismissed claims

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4